कंपनी का अवलोकन
Picard Medical, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry, where it is engaged in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company's primary product offering includes the SynCardia TAH, an artificial heart engineered to function as a replacement for a failed human heart in patients suffering from severe cardiac conditions. As a mid-cap entity, the firm currently maintains a market capitalization of $67.86M, reflecting its position in the specialized medical technology landscape. The organization employs approximately 75 individuals to support its operations, indicating a lean organizational structure typical of early-stage medical device developers. With an annual revenue of $4.77M, the company's scale suggests it is still establishing significant market penetration, as the market cap relative to revenue implies a high valuation multiple often seen in high-growth biotech or niche device sectors before profitability is achieved.
वित्तीय स्वास्थ्य
The financial statements for the trailing twelve months reveal a revenue of $4.77M, while the net income stands at -$32,220,000, and EBITDA is reported at -$13,661,000. The substantial negative gap between the $4.77M revenue and the -$32.22M net income highlights a severe cost structure issue, where expenses significantly exceed income, resulting in a profit margin of 0.0%. Furthermore, the company generated free cash flow of -$10,742,875, which indicates a lack of financial flexibility and a heavy reliance on external capital sources to fund operations and research. When analyzing the margins, the gross margin is -10.0%, the operating margin is -293.8%, and the profit margin is 0.0%; these negative figures collectively suggest that the cost of goods sold and operating expenses are currently driving the company into a loss position despite revenue generation. Regarding the balance sheet, the company holds $2.81M in cash against $616,000 in debt, yet the debt-to-equity ratio is high at 7.73, suggesting a leveraged capital structure relative to its equity base. The current ratio stands at 2.16, which indicates that the company possesses sufficient short-term assets to cover its short-term liabilities, providing a baseline of liquidity despite the operational losses. Additionally, the return on equity is listed as N/A due to the negative equity situation, while the return on assets is -67.3%, revealing that management is currently destroying shareholder value rather than generating returns on the invested capital.
मूल्यांकन आकलन
The trailing P/E ratio and forward P/E ratio are both N/A, which implies that traditional earnings-based valuation metrics cannot be applied given the company's unprofitable status and the absence of expected earnings growth in the near term. Instead, analysts rely on the price-to-book ratio of 8.53, which indicates a significant market premium over the company's book value, suggesting investors are pricing in future growth potential or asset revaluation rather than current earnings power. Alternative valuation metrics such as the price-to-sales ratio of 14.24 and the EV/EBITDA of -4.81 provide further context; the high P/S multiple suggests the market expects substantial revenue expansion, while the negative EV/EBITDA reflects the company's current inability to generate operating cash flow from its earnings before interest, taxes, depreciation, and amortization. The stock price has fluctuated considerably over the past year, trading between a 52-week low of $0.92 and a 52-week high of $13.68. Assuming the current trading price is near the mid-range of this volatility, the security sits significantly below its 52-week high, reflecting the uncertainty surrounding its path to profitability. The beta is listed as N/A, meaning there is insufficient historical data to calculate its volatility relative to the broader market, which limits the ability to assess systematic risk using standard beta coefficients.
Growth & Income
The revenue growth year-over-year is 34.7%, whereas the earnings growth is N/A due to the company's ongoing losses. The fact that earnings growth is not positive while revenue grows at 34.7% implies that the company is expanding its top line but failing to translate this revenue into net income, likely due to high fixed costs or scaling inefficiencies in the manufacturing of its artificial heart devices. As a non-dividend payer, the company does not distribute a dividend yield, which is N/A, nor does it have a payout ratio of 0.0% because it has no earnings to distribute. This structure indicates that the firm reinvests all available capital, including the $2.81M in cash on hand, back into research, development, and manufacturing capacity to support its growth trajectory rather than providing income to shareholders. The overall growth and income profile of Picard Medical, Inc. is characterized by rapid revenue expansion coupled with significant operating losses and a complete absence of dividend distributions, positioning it as a high-risk, high-reward investment dependent on future commercialization success.